Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer EMA Recommends Extension of Indications for Serplulimab MOST POPULAR Spending Review 2020 – Steps in the right direction, but opportunities... November 25, 2020 Medicare Open Enrollment is Almost Here-What You Need to Know for... October 13, 2020 Pioneer in Autism Diagnosis And Treatment Dies At 97 September 21, 2021 Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Load more HOT NEWS The Mediterranean Diet Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... News digest – cancer blood test, gum disease and junk food... Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients...
